Insulin resistance and thrombosis: A cardiologist's view

American Journal of Cardiology

Volumn 84, Issue 1 A, 1999, Pages 37-41

  Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GROWTH FACTOR; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TROGLITAZONE; UROKINASE;

ADULT; ANDROGEN BLOOD LEVEL; ANGIOGRAPHY; ANGIOPLASTY; ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC RESTRICTION; CELL STRAIN HEPG2; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE CONTROL; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FIBRINOLYTIC THERAPY; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULARIZATION;

EID: 0033536235     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00357-4     Document Type: Conference Paper

References (15)

1. Diabetes 1996 Vital Statistics. 1996;29 American Diabetes Association, Chicago.
2. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
3. Bierman E.L. Atherogenesis in diabetes. Arterioscler Thromb. 12:1992;647-656.
4. Schneider D.J., Nordt T.K., Sobel B.E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes. 42:1993;1-7.
5. Schneider D.J., Ricci M.A., Taatjes D.J., Baumann P.Q., Reese J.C., Leavitt B.J., Absher P.M., Sobel B.E. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol. 17:1997;3294-3301.
6. Schneider D.J., Sobel B.E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I implications for vascular disease in hyperinsulinemic states . Proc Natl Acad Sci USA. 88:1991;9959-9963.
7. Nordt T.K., Sawa H., Fujii S., Sobel B.E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 91:1995;764-770.
8. Calles-Escandon J., Mirza S.A., Sobel B.E., Schneider D.J. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 47:1998;290-293.
9. Calles-Escandon J., Ballor D., Harvey-Berino J., Ades P., Tracy R., Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr. 64:1996;7-11.
10. McGill J.B., Schneider D.J., Arfken C.L., Lucore C.L., Sobel B.E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 43:1994;104-109.
11. Rozenman Y., Sapoznikov D., Mosseri M., Gilon D., Lotan C., Nassar H., Weiss A.T., Hasin Y., Gotsman M.S. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus a clue to the explanation of the results of the BARI study . J Am Coll Cardiol. 30:1997;1420-1425.
12. Ferguson J.J. NHLBI BARI clinical alert on diabetics treated with angioplasty. Circulation. 92:1995;3371.
13. Sobel B.E., Woodcock-Mitchell J., Schneider D.J., Holt R.E., Marutsuka K., Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients a potential factor predisposing to thrombosis and its persistence . Circulation. 97:1998;2213-2221.
14. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., Polonsky K.S. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116.
15. Minimakawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 83:1998;1818-1820.